Available Trials

---

• Breast
• Cholangiocarcinoma
• Endometrial
• Head/Neck
• Hematology
• Lung - Non-Small Cell Lung
• Lung - Small Cell Lung
• Lymphoma
• Solid Tumor
• STAR: Selected Trials Available for Accelerated Four Week Rollout

---

Breast

• USOR 22159 - Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
  

  Available at Arlington Heights, Niles

---

Cholangiocarcinoma

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles

---

Endometrial

• USOR 22242 - Ph3 Selin P53 Endo Carcinoma

  A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
  

  Available at Arlington Heights, Niles

---

Head/Neck

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

---

Hematology

• USOR 22311 - CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

  Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
  

  Available at Niles, Arlington Heights

---

Lung - Non-Small Cell Lung

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 23235 - Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

  A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)
  

  Available at Arlington Heights, Niles

• USOR 23074 - Ph3 SGN-B6A vs docetaxel NSCLC

  A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
  

  Available at Arlington Heights, Niles

• USOR 22229 - Ph3 Dato-Dxd Pembro PD-L1 < 50% NSCLC (TL07)

  A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
  

  Available at Arlington Heights, Niles

• USOR 21541 - Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

  A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
  

  Available at Arlington Heights, Niles

• USOR 22198 - STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

  (FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
  

  Available at Arlington Heights, Niles

• USOR 22285 - MYLUNG Consortium Part 3: Observational Study

  Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)
  

  Available at Arlington Heights, Niles

• USOR 21498 - STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

  A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
  

  Available at Arlington Heights

• USOR 20412 - STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

  A Placebo-Controlled, Double-Blinded, Randomized, Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC (LIBRETTO-432)(J2G-MC-JZJX)
  

  Available at Arlington Heights, Niles

• USOR 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

  A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)
  

  Available at Arlington Heights, Niles

---

Lung - Small Cell Lung

• USOR 22136 - Ph3 HLX10 Carbo Cisp-Etop LS-SCLC

  A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)
  

  Available at Arlington Heights, Niles

• USOR 23243 - Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

  A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)
  

  Available at Arlington Heights, Niles

---

Lymphoma

• USOR 22041 - Ph2 Epco r/r B-Cell Lymph out pt

  A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
  

  Available at Arlington Heights, Niles

• USOR 19062 - Ph 1b/3 Taze w/ R2 R/R Fol Lymph

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
  

  Available at Arlington Heights, Niles

---

Solid Tumor

• USOR 23332 - STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes

  A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)
  

  Available at Arlington Heights

• USOR 23292 - STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

  A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)
  

  Available at Arlington Heights, Niles

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

• USOR 22311 - CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

  Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
  

  Available at Niles, Arlington Heights

---

STAR: Selected Trials Available for Accelerated Four Week Rollout

• USOR 23332 - STAR Ph2 study of AK117 in combo with azacitidine in patients with myelodysplastic syndromes

  A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)
  

  Available at Arlington Heights

• USOR 23292 - STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

  A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)
  

  Available at Arlington Heights, Niles

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 18263 - STAR Zanu in Acala Intolerant B-Cell

  A Phase 2, Multicenter, Single-Arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
  

  Available at Arlington Heights, Niles

• USOR 20412 - STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

  A Placebo-Controlled, Double-Blinded, Randomized, Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC (LIBRETTO-432)(J2G-MC-JZJX)
  

  Available at Arlington Heights, Niles